Acumen Pharmaceuticals, Inc. (ABOS)

Market Cap	72.08M
Revenue (ttm)	n/a
Net Income (ttm)	-102.33M
Shares Out	60.57M
EPS (ttm)	-1.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,427
Open	1.240
Previous Close	1.230
Day's Range	1.150 - 1.240
52-Week Range	1.100 - 4.060
Beta	0.02
Analysts	Strong Buy
Price Target	7.33 (+515.97%)
Earnings Date	Mar 27, 2025

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2021
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: ABOS
• Website: https://acumenpharm.com

Analyst Forecast

According to 3 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price forecast is $7.33, which is an increase of 515.97% from the latest price.

Price Target

$7.33

(515.97% upside)

Analyst Consensus: Strong Buy